CD8A and neoplasm: In this context, it has been reported that tumour regression following therapeutic PD-1 blockade requires pre-existing CD8+ T lymphocytes that are negatively regulated by PD-1/PD-ligand 1 (PD-L1)-mediated adaptive immune resistance7.